Liver metastases as a first manifestation of gastrointestinal stromal tumour (GIST)
More details
Hide details
Department of Internal Medicine, Medical University, Lublin, Poland
I Department of Radiology, Medical University Lublin
Polandal University of Lublin, Poland
Corresponding author
Andrzej Prystupa   

Department of Internal Medicine, Medical University, Staszica 11, 20-081 Lublin, Poland.
J Pre Clin Clin Res. 2012;6(1):57-60
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumour of the gastrointestinal tract. Liver metastasis and diffuse intraabdominal spread are typical manifestation of advanced malignancy. A 59-year-old female patient was admitted to the Internal Department with synchronous liver metastases. Clinical examination revealed a palpable abdominal mass in the left epigastrum. Gastroscopy examination revealed an advanced neoplasmatical tumour of the stomach. The histological findings showed GIST with strong CD117 and CD34 reactivity. GIST was characterised by oncogenic mutations of the KIT receptor tyrosine kinase. Imatinib (tyrosine kinase inhibitor) was used in the treatment of metastatic GIST.
Ye Y, Gao Z, Poston GJ, Wang S. Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST)-review. J Cancer Surg.EJSO 2009; 8: 787-792.
Stamatakos M, Douzinas E, Stefanaki Ch, Safioleas P, Polyzou E, Levidou G, Safioleas M. Gastrointestinal stromal tumor – review. World J Surgical Oncology 2009; 7-61.
Dirnhofer S, Leyvraz S: Current standard and progress in understanding and treatment of GIST. Swiss Medical Weekly 2009; 139(7-8): 90-102.
Pesqueira Fontan PM, Molinos Castro S, Caro Narrilos C, Pardavila Gomez R. Metastasis hepaticas: una forma de presentacion de GIST. (Hepatic metastases: a way of GIST presentation). Rev Esp Enferm Dig. 2006; 98: 147-9 (in Spanish).
Suzuki S, Sasajima K, Miyamoto M, Watanabe H, Yokoyama T, Maruyama H et al. Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylat. World J Gastroenterolgy 2008; 21, 14(23): 3763-3767.
Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: potential diagnostic pitfall. Histopathology 2005; 47: 41-47.
Journals System - logo
Scroll to top